• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avidity Biosciences Announces Changes to its Board of Directors

    8/25/21 4:05:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNA alert in real time by email

    LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of directors. Mr. Mosbrooker is an industry leader with expertise in building global commercial organizations, as well as marketing, market access, distribution, and compliance.

    (PRNewsfoto/Avidity Biosciences, Inc.)

    The company also announced the departure of Roderick Wong, M.D. from the board. Dr. Wong, managing partner and chief investment officer at RTW Investments, LP, joined Avidity's board in November 2019 in conjunction with the company's series C financing.

    "We are very pleased to have Eric join our Board further enhancing a commercial perspective that will become increasingly important as our pipeline continues to mature. His experience in rare and genetic diseases is complementary to our existing board members and makes him a welcome addition to the Avidity team," said Sarah Boyce, president and CEO of Avidity. "We are so grateful to Rod for his service over the past year and a half. His expertise was invaluable as we completed our IPO and first follow-on financing."

    Mr. Mosbrooker has expertise in gene therapy, rare metabolic diseases, additional orphan conditions and oncology. Mr. Mosbrooker currently serves as the chief operations officer for Cognoa, leading the commercial, program management, product, and business operations functions. Prior to joining Cognoa, he was the chief commercial officer at Audentes Therapeutics overseeing the gene therapy business unit. Mr. Mosbrooker also served as the senior vice president of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison.

    "I am pleased to join the board of directors at Avidity, especially at such an exciting time for the company," said Mr. Mosbrooker. "Avidity's innovative science, clear strategy and strong AOC platform are a winning combination to improve the lives of people affected by serious diseases. I look forward to working with other board members and the management team to serve patients and their families as Avidity emerges as a leader in the RNA space."

    About Avidity Biosciences

    Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsTM). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1). The FDA has cleared Avidity to proceed with the Phase 1/2 MARINATM trial of AOC 1001 in adults with DM1. Its advancing and expanding pipeline also includes programs in facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular Dystrophy (DMD), muscle atrophy and Pompe disease. The company is planning for AOC 1044, the lead of three programs for the treatment of DMD, and its AOC FSHD program to enter the clinic in 2022.  Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

    Forward-Looking Statements

    Avidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential of the AOCs platform and the progression and maturation of the Company's pipeline of AOCs, the advancement of AOCs into clinical development; the potential for Avidity's AOCs to be commercialized; the potential of AOCs to have a transformative impact on patients with a wide range of serious diseases; and Avidity's strategy to deliver long-term growth. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: Avidity is early in its development efforts and all of its development programs are in the preclinical or discovery stage; Avidity's approach to the discovery and development of product candidates based on its AOC platform is unproven, and the company does not know whether it will be able to develop any products of commercial value; potential delays in the commencement, enrollment and completion of clinical trials;  disruption to its operations from the COVID-19 pandemic; Avidity's dependence on third parties in connection with preclinical testing and product manufacturing; unexpected adverse side effects or inadequate efficacy of its product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; regulatory developments in the United States and foreign countries, including acceptance of INDs and similar foreign regulatory filings and the proposed design of future clinical trials; risks related to integration of new management personnel; and other risks described in prior press releases and in filings with the Securities and Exchange Commission (SEC). Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Company & Investors Contact:

    Kath Gallagher

    [email protected] 

    (858) 401-7900

    Media Contact:

    Cherise Adkins

    [email protected] 

    (301) 267-4161

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-changes-to-its-board-of-directors-301360859.html

    SOURCE Avidity Biosciences, Inc.

    Get the next $RNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNA

    DatePrice TargetRatingAnalyst
    9/17/2025$62.00Buy
    Roth Capital
    7/10/2025$55.00Buy
    Goldman
    6/24/2025$50.00Outperform
    Bernstein
    6/17/2025$55.00Outperform
    Wolfe Research
    6/11/2025$65.00Strong Buy
    Raymond James
    3/13/2025$70.00Buy
    Citigroup
    3/12/2025$72.00Outperform
    BMO Capital Markets
    3/7/2025$70.00Sector Outperform
    Scotiabank
    More analyst ratings

    $RNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $40.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $690.0 million. All of the shares sold

    9/15/25 4:01:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600.0 million. The offering is expected to close on or about September 15, 2025, subject to t

    9/11/25 7:56:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Avidity. There can be no assurance as to whether or when the offering may be completed, or as to the ac

    9/10/25 4:01:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hughes Steven George exercised 2,208 shares at a strike of $10.16 and sold $89,601 worth of shares (2,208 units at $40.58) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/23/25 4:57:37 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Human Resources Officer Mccarthy Teresa exercised 15,000 shares at a strike of $22.34 and sold $621,142 worth of shares (15,000 units at $41.41) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/17/25 4:03:37 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Hughes Steven George exercised 1,542 shares at a strike of $6.57 and sold $70,022 worth of shares (1,542 units at $45.41) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/17/25 4:02:14 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Avidity Biosciences with a new price target

    Roth Capital initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $62.00

    9/17/25 7:57:56 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Avidity Biosciences with a new price target

    Goldman resumed coverage of Avidity Biosciences with a rating of Buy and set a new price target of $55.00

    7/10/25 8:52:40 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Avidity Biosciences with a new price target

    Bernstein initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $50.00

    6/24/25 7:59:27 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    SEC Filings

    View All

    SEC Form 8-K filed by Avidity Biosciences Inc.

    8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/12/25 5:23:24 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Avidity Biosciences Inc.

    424B5 - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/12/25 4:53:54 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Avidity Biosciences Inc.

    424B5 - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/10/25 4:59:56 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Leadership Updates

    Live Leadership Updates

    View All

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

    SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh

    8/5/24 9:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    $RNA
    Financials

    Live finance-specific insights

    View All

    Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting

    Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates

    3/30/23 7:07:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

    Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A

    9/27/22 7:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 1:22:38 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avidity Biosciences Inc.

    SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 9:39:22 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care